PMID- 31116126
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 26
IP  - 7S Suppl 2
DP  - 2020 Oct
TI  - Clinical Effectiveness and Safety of Treatment With Anti-Tumor Necrosis Factor alpha 
      Drugs in a Cohort of Colombian Patients With Rheumatoid Arthritis.
PG  - S123-S130
LID - 10.1097/RHU.0000000000001093 [doi]
AB  - OBJECTIVE: To compare the clinical response at 24 months and evaluate the adverse 
      events (AEs) of patients with rheumatoid arthritis (RA) treated with etanercept 
      50 (injectable solution 50 mg prefilled syringe), etanercept 25 (lyophilized 25 
      mg), infliximab, adalimumab, or golimumab. METHODS: A cohort study was carried 
      out in patients with RA, in treatment with etanercept (injectable solution 50 mg 
      prefilled syringe or lyophilized 25 mg), infliximab, adalimumab, or golimumab. 
      Duration of study: follow-up was carried out for 24 months. The difference of 
      initial and final 28-joint Disease Activity Score, remission incidence, 
      difference of initial and final Health Assessment Questionnaire score, disability 
      recovery, and AE rate were evaluated. RESULTS: The study enrolled 435 patients 
      (108 adalimumab, 107 infliximab, 92 etanercept 25 mg, 81 etanercept 50 mg, and 47 
      golimumab). For etanercept 50, the median difference between basal and at the end 
      of follow-up 28-joint Disease Activity Score was 1.7. For golimumab, it was 1.4; 
      for adalimumab, it was 1.1; for etanercept 25, it was 1.02; and for infliximab, 
      it was 0.96 (p = 0.001). The median difference between basal and final Health 
      Assessment Questionnaire ranged was 1.66 for etanercept 50, 1.34 for etanercept 
      25, 1.3 for golimumab, 1.24 for adalimumab, and 1.07 for infliximab (p = 0.0005). 
      Comparatively, etanercept 50 presented the highest cumulative incidence (77%; 95% 
      confidence interval [CI], 67%-86%) and remission incidence (64 cases per 100 
      person-months; 95% CI, 4.9-8.1 cases per 100 person-months) and the lowest AE 
      rate (8.6 per 100 person-years; 95% CI, 5.3-15 per 100 person-years). 
      CONCLUSIONS: In patients with RA treated with anti-tumor necrosis factor alpha drugs, 
      the highest incidence of remission and the lowest rate of AEs were documented for 
      the cohort exposed to etanercept 50 mg.
FAU - Santos-Moreno, Pedro
AU  - Santos-Moreno P
AD  - From the BIOMAB IPS: Rheumatoid Arthritis Center.
FAU - Sanchez-Vanegas, Guillermo
AU  - Sanchez-Vanegas G
AD  - Fundacion Universitaria de Ciencias de la Salud-FUCS, SIIES: Research and 
      Education in Health, Bogota, Colombia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab/adverse effects
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/diagnosis/drug therapy/epidemiology
MH  - Cohort Studies
MH  - Colombia/epidemiology
MH  - Etanercept/adverse effects
MH  - Humans
MH  - Immunoglobulin G
MH  - Infliximab/adverse effects
MH  - *Pharmaceutical Preparations
MH  - Receptors, Tumor Necrosis Factor/therapeutic use
MH  - Treatment Outcome
EDAT- 2019/05/23 06:00
MHDA- 2021/06/24 06:00
CRDT- 2019/05/23 06:00
PHST- 2019/05/23 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2019/05/23 06:00 [entrez]
AID - 00124743-202010002-00007 [pii]
AID - 10.1097/RHU.0000000000001093 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2020 Oct;26(7S Suppl 2):S123-S130. doi: 
      10.1097/RHU.0000000000001093.